Newsletter sign-up
Does my company subscribe?
Contact Sales:1-800-405-0844
EMARKETER
Log in
Become a ClientGet a DemoPricing
ArticlesPricing

Products

See All Solutions →
By ProductEMARKETER PRO+Analyst Access Program
By Use CaseDetermine Market SizingDevelop StrategiesAllocate BudgetBenchmark PerformanceWin New BusinessDevelop Go-to-Market StrategyStay InformedThought LeadershipSee All Use Cases →
Advertising & Sponsorship
Boost your brand and generate demand with media programs.
Learn More →

Events & Resources

Learning Center
Read through guides, explore resource hubs, and sample our coverage.
Learn More →
Events
Register for an upcoming webinar and track which industry events our analysts attend.
Learn More →
Podcasts
Listen to our podcast, Behind the Numbers for the latest news and insights.
Learn More →

Topics

See All Topics →
Advertising & MarketingSocial MediaContent MarketingEmail MarketingVideoBrowse All →
Ecommerce & RetailEcommerce SalesMcommerceRetail SalesSocial CommerceBrowse All →
Financial ServicesBankingPaymentsFintechWealth ManagementBrowse All →
GeographiesAsia-PacificCentral & Eastern EuropeLatin AmericaMiddle East & AfricaNorth AmericaWestern Europe
HealthValue-Based CareDigital TherapeuticsTelehealthOnline PharmacyBrowse All →
TechnologyConnected Devices5GArtificial Intelligence (AI)Browse All →
More IndustriesReal EstateCustomer ExperienceB2BTravelSmall Business (SMB)Browse All →

Latest Articles

Explore our Research →

Shoppers hate paying for return shipping more than any other part of the process

Article |
 Mar 6, 2026

Doctors expect longer visits as parents seek clarity about pediatric vaccine guidelines

Article |
 Mar 6, 2026

Lowe’s reaches out to Gen Alpha with new rewards program for kids

Article |
 Mar 6, 2026

Meta faces critical questions as AI spending and regulatory scrutiny intensify

Article |
 Mar 6, 2026

J&J launches direct-to-consumer prescription drug site with lower cash prices

Article |
 Mar 6, 2026

The health and fitness industry’s future is subscription-first, not hardware-led

Article |
 Mar 6, 2026

Scam exposure on social platforms threatens brands

Article |
 Mar 6, 2026

Email is consumers’ top marketing channel, but inbox fatigue threatens ROI

Article |
 Mar 6, 2026

How payment providers should react to OpenAI’s Instant Checkout walkback

Article |
 Mar 6, 2026

Capital One joins finance industry layoff trend, sheds 1,100 Discover workers

Article |
 Mar 6, 2026
Browse All →

About

Our Story
Learn more about our mission and how EMARKETER came to be.
Learn More →
Our Clients
Key decision-makers share why they find EMARKETER so critical.
Learn More →
Our People
Take a look into our corporate culture and view our open roles.
Join the Team →
Our Methodology
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More →
Newsroom
See our latest press releases, news articles or download our press kit.
Learn More →
Contact Us
Speak to a member of our team to learn more about EMARKETER.
Contact Us →
EMARKETER

Sales of Mounjaro and Zepbound missed estimates in Q3

Article by Rajiv Leventhal  |  Nov 1, 2024
Download
Sales of Mounjaro and Zepbound missed estimates in Q3
Share
Topics
Digital Health
United States

The news: Eli Lilly reported weaker-than-expected sales in Q3 for its two GLP-1 blockbuster medications, Mounjaro and Zepbound.

  • For Q3 2024, worldwide Mounjaro revenues were $3.11 billion, while Zepbound brought in $1.26 billion in the US.
  • Analysts expected Mounjaro sales at $4.2 billion and $1.69 billion for Zepbound, according to LSEG data cited by Reuters.
  • Zepbound sales slightly decreased quarter over quarter, while sales for Mounjaro slightly increased.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!
EMARKETER

Geographies

EMARKETER

Media Services

Free Content

Contact Us →

Worldwide HQ

One Liberty Plaza9th FloorNew York, NY 100061-800-405-0844

Sales Inquiries

1-800-405-0844sales@emarketer.com

* Copyright © 2026 
EMARKETER Inc. All Rights Reserved.